Human peripheral blood lymphocytes (PBL) isolated from a melanoma patient and were engineered to react with the melanoma antigen glycoprotein 100 (gp100). These PBL are transduced with a retroviral pGCsam vector encoding T-cell receptors specific for gp100, grown in culture, and then transferred back to the patient. These genetically modified PBL may recognize and halt the growth of gp100-expressing melanoma cells. [ ]